Ondansetron Accord Healthcare

Ondansetron, the active ingredient in Ondansetron Accord Healthcare, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adults and children. GNH USA supplies Ondansetron Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways.

- Chemotherapy‑induced nausea and vomiting: helps reduce the frequency and severity of episodes. - Post‑operative nausea and vomiting: decreases the incidence of nausea after surgical procedures. - Radiotherapy‑induced nausea and vomiting: lessens nausea associated with radiation treatment. - Pregnancy‑related nausea: provides symptomatic relief for morning sickness when prescribed. - Hyper‑emesis gravidarum: used as part of a treatment regimen for severe pregnancy‑related vomiting.

Common Side Effects: - Headache: mild to moderate headache may occur. - Constipation: occasional reduced bowel movements. - Diarrhoea: loose stools may be experienced. - Fatigue: feeling of tiredness or low energy. - Dizziness: light‑headed sensations.

Serious or Rare Side Effects: - QT prolongation: potential cardiac rhythm changes detectable on ECG. - Serotonin syndrome: rare condition with agitation, tremor, and hyperreflexia. - Severe allergic reaction: includes rash, itching, swelling, or breathing difficulty. - Hepatic dysfunction: abnormal liver enzyme elevations. - Anaphylaxis: life‑threatening allergic response requiring immediate medical care.

When using Ondansetron, consider the following precautions: - Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be monitored. - Electrolyte assessment: correct potassium, magnesium, and calcium levels before initiating therapy. - Concomitant medications: review all current drugs for potential interactions affecting cardiac rhythm. - Pregnancy and lactation: evaluate risk‑benefit ratio before prescribing to pregnant or breastfeeding women. - Renal or hepatic impairment: dose adjustment may be required based on organ function. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Ondond…